CA2669536A1 — Combinations of ambrisentan and pde5 inhibitors for treating pulmonary arterial hypertension
Assigned to Gilead Sciences Inc · Expires 2008-06-19 · 18y expired
What this patent protects
A method for treating a pulmonary hypertension condition such as pulmonar y arterial hypertension (PAH) in a subject comprises administering to the su bject a therapeutically effective amount of ambrisentan, wherein, at baselin e, time from first diagnosis of the condition in the…
USPTO Abstract
A method for treating a pulmonary hypertension condition such as pulmonar y arterial hypertension (PAH) in a subject comprises administering to the su bject a therapeutically effective amount of ambrisentan, wherein, at baselin e, time from first diagnosis of the condition in the subject is not greater than about 2 years.
Drugs covered by this patent
- Letairis (AMBRISENTAN) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.